An evidence-based BPC-157 protocol covering beginner to advanced dosing (250-750 mcg), exact reconstitution math, injection technique, the TB-500 stack, side effects, and how to verify purity. It cites 10 PubMed studies.
What Is BPC-157? (Mechanism of Action Explained)
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) isolated from a larger protective protein found in human gastric juice. Originally characterized in the early 1990s by Sikiric et al. at the University of Zagreb, it's now one of the most-studied peptides in regenerative medicine ([Sikiric et al., 2018]).
The peptide doesn't bind a single canonical receptor the way a GLP-1 agonist binds GLP-1R. Instead, the published mechanism is a cocktail of downstream effects:
- Angiogenesis acceleration — upregulates VEGFR2 expression in endothelial cells, increasing capillary density at injury sites by 60-80% in tendon-transection models ([Hsieh et al., 2017]).
- Nitric oxide modulation — interacts with the NO system to balance both NO over-production (sepsis-like states) and NO suppression (ischemic states), giving it bidirectional vascular effects.
- Growth-factor potentiation — increases EGR-1 (Early Growth Response 1) and FAK-paxillin signaling, the same pathways that drive fibroblast proliferation and collagen-1A1 deposition during wound repair ([Chang et al., 2014]).
- Gut-brain axis activity — protects against indomethacin-induced gastrointestinal lesions and reverses MPTP-induced Parkinsonian symptoms in rodents, suggesting CNS bioavailability via vagal afferents ([Sikiric et al., 2020]).
The practical translation: BPC-157 doesn't do one thing — it accelerates the existing repair cascade your body already runs.
BPC-157 Dosage Protocol — The Evidence-Based Guide
The dose ranges below mirror what's consistently used across the published rodent and human-anecdotal literature, normalized to a 70 kg adult. Animal studies dose at 10 µg/kg routinely; that maps to ~700 mcg in a 70 kg human, and the widely-used 250-500 mcg range is conservative on that scale.
Beginner protocol — 4-6 week recovery cycle
- Dose: 250 mcg, twice daily (500 mcg/day total)
- Route: Subcutaneous injection (SubQ) into abdominal fat, 2-3 inches lateral of the navel
- Frequency: Morning + evening, ~12 hours apart
- Duration: 4 weeks on / 2 weeks off
- Use cases: First-time researchers; minor tendon strain; gut-related research (e.g., post-NSAID work)
Intermediate protocol — 6-8 week stubborn-injury cycle
- Dose: 500 mcg, twice daily (1,000 mcg/day total)
- Route: SubQ; if studying a specific tendon/joint, inject within 5 cm of the target site
- Frequency: Morning + post-workout (the post-exercise peak in local blood flow may improve site-specific delivery)
- Duration: 6-8 weeks on / 2-4 weeks off
- Use cases: Chronic tendinopathy research; partial-thickness rotator-cuff models
Advanced protocol — full Wolverine stack
- Dose: 500-750 mcg, twice daily (up to 1,500 mcg/day)
- Route: SubQ or intramuscular (IM) for deep-tissue research
- Frequency: AM + PM
- Duration: 8-12 weeks on / 4 weeks off
- Stack with: TB-500 (Thymosin Beta-4 fragment) at 2-2.5 mg twice weekly — see BPC-157 vs TB-500 for the full side-by-side, or the Wolverine Stack guide for the combined protocol.
Half-life and dosing-frequency rationale
BPC-157's pharmacokinetic profile is short. Plasma half-life in rats is ~30 minutes after IV administration, but the biological effect persists for 24+ hours, suggesting tissue binding or downstream signaling that outlasts the parent compound ([Vukojevic et al., 2018]). Twice-daily dosing is the standard not because the peptide circulates for 12 hours but because the receptor-level (or rather, pathway-level) activation has a long tail.
A single morning-only schedule works for maintenance research, but during active healing windows the twice-daily split correlates with the published effect sizes.
How to Reconstitute and Inject BPC-157
Reconstitution math (5 mg vial, 2 mL BAC water)
BPC-157 ships as a lyophilized powder. Most vendors sell 5 mg or 10 mg vials. The common reconstitution is:
- Vial size: 5 mg lyophilized powder
- BAC water added: 2 mL bacteriostatic water (0.9% benzyl alcohol)
- Final concentration: 5 mg / 2 mL = 2.5 mg/mL = 2,500 mcg/mL
- Per-100-unit syringe draw at 250 mcg dose: 250 / 2,500 × 1.0 mL = 0.1 mL = 10 units on a U-100 insulin syringe
- Per-100-unit syringe draw at 500 mcg dose: 0.2 mL = 20 units
If you're using a 10 mg vial reconstituted with 2 mL of BAC water, the concentration doubles (5 mg/mL = 5,000 mcg/mL) and the per-dose draw halves: 5 units for 250 mcg, 10 units for 500 mcg.
The Reconstitution Calculator will run this math for any vial-size + BAC-volume + dose combination, and a step-by-step photo walkthrough lives at How to Reconstitute BPC-157.
Subcutaneous injection technique
- Swab the injection site with 70% isopropyl alcohol; let it dry 30 seconds.
- Use a fresh insulin syringe (29-31 gauge, 5/16" or 1/2" needle) per injection.
- Pinch a 1-inch fold of skin to lift the subcutaneous layer away from muscle.
- Insert at 45° (or 90° if using a short 5/16" needle on a thinner subject).
- Aspirate is unnecessary for subcutaneous; inject slowly over 3-5 seconds.
- Apply gentle pressure with a clean gauze pad after withdrawal.
- Rotate sites — never inject the same spot twice in a row. Lipohypertrophy (fatty thickening) is the most common consequence of repeated single-site injection.
Storage
- Lyophilized (unmixed): room temperature is acceptable for short-term; refrigerate (2-8°C) for long-term.
- Reconstituted: refrigerate at 2-8°C, never freeze (freeze-thaw destroys the peptide bond integrity).
- Use within 28 days of reconstitution at 2-8°C. After 28 days, peptide degradation accelerates measurably ([Park et al., 2019]).
- Discard any vial that goes cloudy, develops particulates, or changes color.
What the Research Shows — Injury by Injury
Tendon and ligament repair
The single most-replicated BPC-157 finding is accelerated tendon-to-bone healing. In a Achilles-transection rat model, BPC-157 administered 10 µg/kg/day for 14 days produced full functional restoration of the gastrocnemius-Achilles complex by day 14, vs. partial recovery in controls. Histology showed organized type-I collagen alignment along the load axis at the BPC-157-treated insertion ([Krivic et al., 2008]).
For researchers, this is the strongest indication: if you're working with tendon strain, partial tear, or post-surgical tendon repair, BPC-157 has the deepest evidence base.
Gut and liver
BPC-157 was originally characterized as a gastroprotective compound. In rats given indomethacin (a strong NSAID) at ulcerogenic doses, prophylactic BPC-157 (10 µg/kg) reduced gastric lesion area by ~70% and accelerated mucosal healing ([Sikiric et al., 2013]). The same review noted protection against ethanol-induced and stress-induced lesions across multiple models.
The practical anecdotal use case in the biohacking community is post-NSAID gut research and IBD-adjacent work — the published mechanism supports this, but human RCTs remain absent.
Vascular and neural repair
A more recent line of work shows BPC-157 reverses dopaminergic toxicity in MPTP-induced Parkinsonian rats and reduces lesion size in middle-cerebral-artery-occlusion stroke models — both effects abolished when nitric oxide synthase is blocked, confirming the NO axis as a primary mechanism ([Sikiric et al., 2020]).
BPC-157 + TB-500 Stack Protocol
The two peptides hit complementary pathways: BPC-157 drives angiogenesis and growth-factor cascades, while TB-500 (a synthetic fragment of Thymosin Beta-4) drives actin sequestration and cellular migration. Together they cover both the proliferation and the remodeling phases of soft-tissue healing.
A representative stack for advanced research:
- BPC-157: 500 mcg twice daily, SubQ
- TB-500: 2-2.5 mg twice weekly (Mon + Thu), SubQ
- Cycle: 8 weeks on / 4 weeks off
Full side-by-side: BPC-157 vs TB-500. Detailed stack timing: The Wolverine Stack guide.
Side Effects, Safety Profile, and Contraindications
BPC-157 has one of the cleanest safety profiles in the research-peptide space. Across decades of rodent studies at doses up to 1,000× the human-equivalent research dose, no significant adverse effects (cardiovascular, hepatic, renal, hematologic, oncologic) have been reported in controlled designs ([Sikiric et al., 2018]).
That said, no human RCT has been published. Every claim about human safety is either animal-model extrapolation or self-reported user data. The honest framing:
- Common (mild, self-resolving): transient injection-site soreness, occasional dizziness in the first week.
- Theoretical (animal-data-only): angiogenesis acceleration could in principle vascularize a latent neoplasm; no published case ties BPC-157 to clinical neoplasm onset, but this is the most-cited theoretical concern.
- Contraindicated populations: active malignancy (until cleared by an oncologist), pregnancy/lactation (no developmental data), known peptide allergy.
- Interactions: none reported, but the angiogenic effect could theoretically amplify VEGF-axis cancer therapies — disclose use to any oncology team.
Discontinue immediately and seek medical attention for: persistent injection-site redness/swelling >48 hours (possible infection), unexplained edema, vision changes, abnormal heart rhythm.
How to Source Quality BPC-157 (Purity Testing)
The BPC-157 market is unregulated. Vendor quality varies from pharmaceutical-grade (≥98% HPLC purity, third-party tested) to outright bunk (under-dosed or wrong-peptide reagents). Three signals separate the real vendors from the rest:
- Per-batch HPLC Certificate of Analysis (COA). A real vendor publishes a current-batch COA showing purity ≥98% by HPLC, mass spec confirming the 1419 Da molecular weight, and water content under 6%. Generic "we test our products" language without per-batch documents is a red flag. The BHG COA Reader parses uploaded COAs and flags missing fields.
- Independent third-party verification. Vendors who pay for unaffiliated lab testing (Janoshik, AlphaLabs, Auxilium) publish those results. In-house "QC" without external verification is one step above marketing copy.
- Trust score and community feedback. Cross-reference vendor reviews on independent sites. The BHG Compare page shows live pricing across 9+ verified vendors with trust scores 0-100, current stock status, and the price-per-mg breakdown.
Price anchoring: a 5 mg vial of pharmaceutical-grade BPC-157 typically falls in the $30-50 range as of mid-2026. Anything under $20 is either expired stock, under-dosed, or fundamentally not what the label claims.
Frequently Asked Questions
How long until I see results from BPC-157?
In rodent tendon-injury models, measurable effects appear within 4-7 days at 10 µg/kg/day. User-reported recovery timelines from the biohacking community track similar — 1-2 weeks for acute soft-tissue research, 4-6 weeks for chronic stubborn-injury research.
Is BPC-157 better SubQ or IM?
SubQ is the default and works for nearly all use cases. IM is reserved for deep-muscle or deep-joint research where local concentration matters more than systemic delivery. The published rodent literature uses both routes interchangeably with similar effect sizes.
Should I inject BPC-157 close to the injury?
The evidence is mixed. Some rat data suggests local injection produces ~20-30% larger local effect, but the systemic effect is strong enough that abdominal SubQ works for most research targets. If the target is a specific tendon you can identify by palpation, injecting within 5 cm of the site is reasonable.
Can I mix BPC-157 and TB-500 in the same syringe?
No — they're typically reconstituted separately and dosed on different days because TB-500 is twice-weekly and BPC-157 is twice-daily. Mixing also forecloses on dose adjustment of one without the other.
What's the BPC-157 oral version (KPV, BPC-157 Arginate)?
"Stable BPC-157" / arginate-salt formulations claim oral bioavailability. The peer-reviewed evidence for true oral activity remains thin compared to the SubQ/IM literature. For research purposes, SubQ is what the published data supports.
How do I know if my BPC-157 is real?
Three-step check: (1) per-batch HPLC COA showing ≥98% purity, (2) third-party lab verification, (3) the BHG vendor trust score ≥70. If a vendor can't produce all three, treat the product as unverified.
For research purposes only. Not medical advice. BPC-157 is not approved by the FDA, EMA, or other major regulatory agencies for human use. Always consult a qualified clinician before starting any protocol. See the BHG safety methodology for our full vendor-vetting and content-review process.
Related Articles
New guides, by email
New compound guides and research notes when we publish them. No set schedule. Unsubscribe anytime.
No spam. Unsubscribe anytime.
Founder of BodyHackGuide. Writes the site's guides on peptide research, nootropics and vendor quality, and posts as u/BioChonch on Reddit.
Discussion
Sign in to join the discussion
No comments yet. Be the first to share your thoughts!